Trials (Institut Jules Bordet) - Revision history

Lucas: Update categories.

2025-12-06T12:41:20Z

Update categories.

← Older revision		Revision as of 12:41, 6 December 2025
Line 767:		Line 767:

	'''NCTID''': NCT03		'''NCTID''': NCT03
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Lucas: Update categories.

2025-12-02T13:59:05Z

Update categories.

← Older revision		Revision as of 13:59, 2 December 2025
Line 1:		Line 1:
	{{forpatients}}		<span style="display:none">forpatients</span>
	{{forproviders}}		<span style="display:none">forproviders</span>
	{{forresearchers}}		<span style="display:none">forresearchers</span>
	{{belgiumcountry}}		<span style="display:none">belgiumcountry</span>
	{{hospital}}		<span style="display:none">hospital</span>
	{{cancer center}}		<span style="display:none">cancer center</span>
	Go back to [[Institut Jules Bordet]] page		Go back to [[Institut Jules Bordet]] page

Francine at 11:36, 2 December 2025

2025-12-02T11:36:16Z

← Older revision		Revision as of 11:36, 2 December 2025
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
	{{~~belgium~~}}		{{belgiumcountry}}
	{{hospital}}		{{hospital}}
	{{cancer center}}		{{cancer center}}

Victor at 18:09, 6 November 2024

2024-11-06T18:09:19Z

← Older revision		Revision as of 18:09, 6 November 2024
Line 3:		Line 3:
	{{forresearchers}}		{{forresearchers}}
	{{belgium}}		{{belgium}}
			{{hospital}}
			{{cancer center}}
	Go back to [[Institut Jules Bordet]] page		Go back to [[Institut Jules Bordet]] page

Victor at 16:49, 5 November 2024

2024-11-05T16:49:40Z

← Older revision		Revision as of 16:49, 5 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{belgium}}
	Go back to [[Institut Jules Bordet]] page		Go back to [[Institut Jules Bordet]] page

Francine at 13:00, 2 May 2024

2024-05-02T13:00:04Z

Show changes

Francine at 13:37, 4 January 2024

2024-01-04T13:37:08Z

← Older revision		Revision as of 13:37, 4 January 2024
Line 753:		Line 753:

	'''NCTID''': NCT01513109		'''NCTID''': NCT01513109
	'''Title''': [[hasTrialTitle::A Phase I ~~and~~ II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT)]].		'''Title''': [[hasTrialTitle::A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 plus AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT)]].
	'''Study Summary''': The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as post-consolidation therapy in patients with WT1-positive Acute Myeloid Leukemia. The study will also evaluate the clinical activity and immune response of this approach in bad risk patients in CR1 and all patients in CR2 or CR3, non eligible for an allogeneic Hematopoietic Stem Cell Transplantation		'''Study Summary''': The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as post-consolidation therapy in patients with WT1-positive Acute Myeloid Leukemia. The study will also evaluate the clinical activity and immune response of this approach in bad risk patients in CR1 and all patients in CR2 or CR3, non eligible for an allogeneic Hematopoietic Stem Cell Transplantation
	'''Sponsor''': Jules Bordet Institute		'''Sponsor''': Jules Bordet Institute

Francine at 13:36, 4 January 2024

2024-01-04T13:36:01Z

← Older revision		Revision as of 13:36, 4 January 2024
Line 753:		Line 753:

	'''NCTID''': NCT01513109		'''NCTID''': NCT01513109
	'''Title''': [[hasTrialTitle::A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT)]].		'''Title''': [[hasTrialTitle::A Phase I and II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT)]].
	'''Study Summary''': The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as post-consolidation therapy in patients with WT1-positive Acute Myeloid Leukemia. The study will also evaluate the clinical activity and immune response of this approach in bad risk patients in CR1 and all patients in CR2 or CR3, non eligible for an allogeneic Hematopoietic Stem Cell Transplantation		'''Study Summary''': The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as post-consolidation therapy in patients with WT1-positive Acute Myeloid Leukemia. The study will also evaluate the clinical activity and immune response of this approach in bad risk patients in CR1 and all patients in CR2 or CR3, non eligible for an allogeneic Hematopoietic Stem Cell Transplantation
	'''Sponsor''': Jules Bordet Institute		'''Sponsor''': Jules Bordet Institute

Francine at 13:33, 4 January 2024

2024-01-04T13:33:57Z

Show changes

Francine at 13:23, 4 January 2024

2024-01-04T13:23:58Z

← Older revision		Revision as of 13:23, 4 January 2024
Line 5:		Line 5:

	'''NCTID''': NCT04966715		'''NCTID''': NCT04966715
	'''Title''': Inferior Epigastric Lymph Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Colorectal Peritoneal Metastases		'''Title''': [[hasTrialTitle::Inferior Epigastric Lymph Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Colorectal Peritoneal Metastases]]
	'''Study Summary''': In this study, the investigators propose to systematically collect and analyse epigastric lymph nodes during complete cytureductive surgery in patients with colorectal carcinomatosis, in order to define their role in the dissemination of colorectal metastases		'''Study Summary''': In this study, the investigators propose to systematically collect and analyse epigastric lymph nodes during complete cytureductive surgery in patients with colorectal carcinomatosis, in order to define their role in the dissemination of colorectal metastases
	'''Sponsor''': Jules Bordet Institute		'''Sponsor''': Jules Bordet Institute
Line 16:		Line 16:

	'''NCTID''': NCT04379817		'''NCTID''': NCT04379817
	'''Title''': Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients		'''Title''': [[hasTrialTitle::Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients]]
	'''Study Summary''': This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide.		'''Study Summary''': This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide.
	'''Sponsor''': Jules Bordet Institute		'''Sponsor''': Jules Bordet Institute
Line 27:		Line 27:

	'''NCTID''': NCT01709487		'''NCTID''': NCT01709487
	'''Title''': Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy		'''Title''': [[hasTrialTitle::Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy]]
	'''Study Summary''': First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal debulking.		'''Study Summary''': First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal debulking.
	'''Sponsor''': Jules Bordet Institute		'''Sponsor''': Jules Bordet Institute